Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine response rate after 8 cycles of D-KRd (daratumumab,
carfilzomib, lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma.